

Sandro Pignata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6623824/publications.pdf>

Version: 2024-02-01

228
papers

13,906
citations

31976

53
h-index

24258

110
g-index

236
all docs

236
docs citations

236
times ranked

13360
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
2	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
3	Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies. <i>Annals of Surgery</i> , 1999, 230, 1.	4.2	1,012
4	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. <i>Journal of Clinical Oncology</i> , 2010, 28, 3323-3329.	1.6	500
5	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 437-448.	27.0	375
6	Early and Late Complications After Radiofrequency Ablation of Malignant Liver Tumors in 608 Patients. <i>Annals of Surgery</i> , 2004, 239, 450-458.	4.2	336
7	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 641-655.	2.5	336
8	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
9	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3374-3382.	1.6	302
10	Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 890-896.	1.6	259
11	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 404-416.	0.6	241
12	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	10.7	215
13	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	10.7	205
14	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	2.5	186
15	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 609-619.	10.7	186
16	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	1.6	183
17	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	1.6	182
18	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9845-9850.	7.1	176

#	ARTICLE	IF	CITATIONS
19	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	7.7	158
20	Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2635-2642.	1.6	149
21	Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer. <i>Cancer</i> , 2010, 116, 1893-1900.	4.1	144
22	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 561-568.	10.7	141
23	Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4469-4474.	1.6	131
24	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 919-936.	2.8	127
25	Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. <i>Cancer Treatment Reviews</i> , 2017, 59, 109-116.	7.7	122
26	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2881-2887.	1.6	114
27	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <i>Cancer Treatment Reviews</i> , 2016, 48, 61-68.	7.7	102
28	Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. <i>BMC Cancer</i> , 2006, 6, 5.	2.6	101
29	Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3582.	1.6	97
30	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 1137-1146.	10.7	97
31	Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. <i>Journal of Clinical Oncology</i> , 2019, 37, 2437-2448.	1.6	96
32	Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 10357.	3.3	87
33	First-line treatment of advanced ovarian cancer: current research and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 47-60.	2.4	84
34	Chemotherapy in epithelial ovarian cancer. <i>Cancer Letters</i> , 2011, 303, 73-83.	7.2	83
35	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	1.6	82
36	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 267-276.	10.7	79

#	ARTICLE	IF	CITATIONS
37	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 781-791.	4.2	78
38	Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy. <i>Cancer Treatment Reviews</i> , 2015, 41, 136-143.	7.7	76
39	Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1300-1307.	1.6	76
40	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	1.6	75
41	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 229-236.	4.4	72
42	Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 63-67.	2.2	71
43	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. <i>BJU International</i> , 2013, 112, 686-696.	2.5	70
44	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	2.8	70
45	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
46	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
47	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	1.6	66
48	Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix. <i>Journal of Clinical Oncology</i> , 1999, 17, 756-756.	1.6	65
49	Olaparib as maintenance therapy in patients with BRCA 1&2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020, 156, 38-44.	1.4	62
50	Effect of Chemotherapy with 5-Fluorouracil on Intestinal Permeability and Absorption in Patients with Advanced Colorectal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2001, 32, 228-230.	2.2	60
51	Gynecologic Cancer InterGroup (GCG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S9-S13.	2.5	59
52	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. <i>Oncotarget</i> , 2017, 8, 77110-77120.	1.8	59
53	Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. , 1997, 73, 880-884.		57
54	Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, S109-S114.	2.2	57

#	ARTICLE	IF	CITATIONS
55	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1820.	3.7	57
56	A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. <i>Oncologist</i> , 2020, 25, e311-e320.	3.7	56
57	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5506-5506.	1.6	55
58	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	4.4	51
59	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	1.4	51
60	Ovarian cancer in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 49, 77-86.	4.4	50
61	Treatment of recurrent epithelial ovarian cancer. <i>Cancer</i> , 2019, 125, 4609-4615.	4.1	49
62	Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 243-249.	4.4	48
63	Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. <i>European Journal of Cancer</i> , 2013, 49, 3831-3838.	2.8	48
64	Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-12.	2.5	48
65	Is human hepatocellular carcinoma a hormone-responsive tumor?. <i>World Journal of Gastroenterology</i> , 2008, 14, 1682.	3.3	46
66	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5511-5511.	1.6	45
67	Gynecological Malignancies in Elderly Patients: Is Age 70 a Limit to Standard-Dose Chemotherapy? An Italian Retrospective Toxicity Multicentric Study. <i>Gynecologic Oncology</i> , 2002, 85, 445-450.	1.4	44
68	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008, 8, 252.	2.6	44
69	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1063-1070.	2.5	43
70	Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1721.	2.4	43
71	Gynecologic Cancer InterGroup (GFIG) Consensus Review for Cervical Adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S96-S101.	2.5	41
72	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	5.9	40

#	ARTICLE	IF	CITATIONS
73	European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 476-478.	2.5	38
74	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. <i>Gynecologic Oncology</i> , 2017, 144, 256-259.	1.4	38
75	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	3.6	38
76	Soluble Interleukin-2 Receptor Levels in Hepatocellular Cancer: a More Sensitive Marker Than Alfa Fetoprotein. <i>Annals of Surgical Oncology</i> , 1999, 6, 178-185.	1.5	37
77	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018, 9, 19861-19873.	1.8	37
78	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
79	Constitutive Insulin-like Growth Factor-II Expression Interferes with the Enterocyte-like Differentiation of CaCo-2 Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 8108-8114.	3.4	35
80	New treatment approaches in renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2009, 20, 893-900.	1.4	35
81	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. <i>Frontiers in Pharmacology</i> , 2016, 7, 123.	3.5	35
82	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	7.7	35
83	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA5503-LBA5503.	1.6	35
84	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , 2013, 130, 289-294.	1.4	34
85	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	6.3	33
86	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 430-433.	2.5	33
87	Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. <i>Anticancer Research</i> , 2005, 25, 3501-5.	1.1	33
88	Ornithine decarboxylase and diamine oxidase in human colon carcinoma cell line CaCo-2 in culture. <i>Gastroenterology</i> , 1989, 97, 888-894.	1.3	32
89	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 233-241.	4.4	32
90	High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	32

#	ARTICLE	IF	CITATIONS
91	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	4.4	32
92	First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 228-233.	2.2	31
93	Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 283-286.	1.6	30
94	Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer. <i>Oncology</i> , 2006, 71, 320-326.	1.9	30
95	Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. <i>Annals of Oncology</i> , 2011, 22, viii40-viii44.	1.2	30
96	Olaparib, PARP1 inhibitor in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1575-1584.	4.1	30
97	The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 33-44.	4.4	29
98	Practice Patterns of Radiotherapy in Cervical Cancer Among Member Groups of the Gynecologic Cancer Intergruop (GCIG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 485-490.	0.8	29
99	Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. <i>Gynecologic Oncology</i> , 2017, 144, 72-76.	1.4	28
100	Immunotherapy in cervix cancer. <i>Cancer Treatment Reviews</i> , 2020, 90, 102088.	7.7	28
101	Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 35-46.	4.4	27
102	Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1923.	7.1	27
103	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
104	<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6123-6135.	1.9	25
105	Treatment of recurrent epithelial ovarian cancer. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 421.	2.0	24
106	Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study. <i>Oncology</i> , 2011, 81, 104-112.	1.9	24
107	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 48.	8.6	24
108	Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2017, 28, 104-109.	1.4	24

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. PLoS ONE, 2018, 13, e0199642.	2.5	23
110	European Network of Gynaecological Oncological Trial Groupsâ€™ Requirements for Trials Between Academic Groups and Industry Partnersâ€™ First Update 2015. International Journal of Gynecological Cancer, 2015, 25, 1328-1330.	2.5	22
111	Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. Critical Reviews in Oncology/Hematology, 2016, 97, 335-348.	4.4	22
112	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer, 2006, 6, 202.	2.6	21
113	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. Future Oncology, 2016, 12, 2071-2075.	2.4	21
114	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. Critical Reviews in Oncology/Hematology, 2019, 139, 87-90.	4.4	21
115	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. Cancer Treatment Reviews, 2020, 90, 102107.	7.7	21
116	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treatment Reviews, 2021, 100, 102294.	7.7	21
117	Interaction of Putrescine with Nuclear Oligopeptides in the Enterocyte-Like Caco-2 Cells. Digestion, 1999, 60, 255-261.	2.3	20
118	Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup Study. International Journal of Gynecological Cancer, 2009, 19, 163-167.	2.5	20
119	Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9). Oncology, 2014, 86, 351-358.	1.9	20
120	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancerâ€™ The GCIg Symptom Benefit Study. Oncologist, 2017, 22, 1117-1124.	3.7	20
121	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. Journal of Gynecologic Oncology, 2020, 31, e92.	2.2	20
122	Obesity and Cancer: Biological Links and Treatment Implications. Current Cancer Drug Targets, 2018, 18, 231-238.	1.6	19
123	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecologic Oncology, 2019, 153, 535-540.	1.4	19
124	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/ManGO-OV2A study. International Journal of Gynecological Cancer, 2021, 31, 875-882.	2.5	19
125	Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer, 2006, 6, 196.	2.6	18
126	Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer. Oncology, 2016, 90, 29-35.	1.9	17

#	ARTICLE	IF	CITATIONS
127	Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis. <i>European Journal of Cancer</i> , 2020, 137, 136-143.	2.8	17
128	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17
129	Modifications in enterocyte diamine oxidase distribution induced by heparin in the rat. <i>Biochemical Pharmacology</i> , 1989, 38, 47-49.	4.4	16
130	FEZ1/LZTS1 protein expression in ovarian cancer. <i>Journal of Cellular Physiology</i> , 2010, 222, 382-386.	4.1	16
131	Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. <i>Cancers</i> , 2019, 11, 1584.	3.7	16
132	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	3.3	16
133	The Role of Chemotherapy in the Management of Gastric Cancer. <i>Journal of Clinical Gastroenterology</i> , 2000, 30, 364-371.	2.2	16
134	Postheparin Plasma Diamine Oxidase in Subjects with Small Bowel Disease. <i>Digestion</i> , 1988, 41, 46-54.	2.3	15
135	Levovist-enhanced Doppler Sonography Versus Spiral Computed Tomography to Evaluate Response to Percutaneous Ethanol Injection in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2000, 31, 164-168.	2.2	15
136	A phase 2 multicenter study of irinotecan and cisplatin as neoadjuvant treatment in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1569-75.	2.5	15
137	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	1.8	15
138	Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer. <i>Oncotarget</i> , 2015, 6, 19328-19335.	1.8	15
139	Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 23-30.	4.4	14
140	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	3.2	14
141	COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted?. <i>Frontiers in Oncology</i> , 2020, 10, 1571.	2.8	14
142	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 331.	3.5	13
143	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591881835.	3.2	13
144	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13

#	ARTICLE	IF	CITATIONS
145	A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer. <i>Oncologist</i> , 2021, 26, e658-e668.	3.7	13
146	Hypergastrinemia in rats with azoxymethane-induced colon cancers. <i>International Journal of Cancer</i> , 1995, 61, 223-226.	5.1	12
147	The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1585.	3.0	12
148	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	2.5	12
149	Testicular and testicular adnexa tumors in the elderly. <i>Anti-Cancer Drugs</i> , 2013, 24, 228-236.	1.4	11
150	1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer. <i>Tumori</i> , 2017, 103, 525-536.	1.1	11
151	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 297.	8.6	11
152	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	2.8	11
153	Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". <i>Frontiers in Pharmacology</i> , 2016, 7, 287.	3.5	10
154	Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. <i>Gynecologic Oncology</i> , 2016, 140, 425-429.	1.4	10
155	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019, 105, 3-12.	1.1	10
156	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	2.8	10
157	Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. <i>Oncotarget</i> , 2016, 7, 82741-82756.	1.8	10
158	Cyclo-Oxygenase Inhibition in Colorectal Adenomas and Cancer. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 281-287.	2.2	9
159	Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for) Tj ETQq1 1 0,784314 rgBT /Ovar	2.8	9
160	Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy. <i>Analytical Cellular Pathology</i> , 2016, 2016, 1-5.	1.4	9
161	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	1.4	9
162	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). <i>Gynecologic Oncology</i> , 2021, 161, 755-761.	1.4	9

#	ARTICLE	IF	CITATIONS
163	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).. Journal of Clinical Oncology, 2014, 32, 5503-5503.	1.6	9
164	Plasma postheparin diamine oxidase in patients with small intestinal lymphoma. Cancer, 1991, 67, 511-515.	4.1	8
165	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. Cancer Chemotherapy and Pharmacology, 2009, 64, 1021-1027.	2.3	8
166	A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. Cancer Chemotherapy and Pharmacology, 2011, 68, 1347-1353.	2.3	8
167	Surveillance Policy for Stage IA Malignant Ovarian Germ Cell Tumors in Children and Young Adults. Journal of Clinical Oncology, 2014, 32, 2814-2815.	1.6	8
168	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 2018, 29, 1189-1194.	1.2	8
169	The clinical and translational research activities at the INT "IRCCS" Fondazione Pascale cancer center (Naples, Italy) during the COVID-19 pandemic. Infectious Agents and Cancer, 2020, 15, 69.	2.6	8
170	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells, 2020, 9, 903.	4.1	8
171	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2021, 107, 100-109.	1.1	8
172	Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2021, 31, 1242-1247.	2.5	8
173	Stage I juvenile granulosa cell tumors of the ovary: A multicentre analysis from the MITO-9 study. European Journal of Surgical Oncology, 2021, 47, 1705-1709.	1.0	8
174	Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. Archives of Dermatological Research, 2004, 296, 141-142.	1.9	7
175	Fine-needle cytology of metastatic endometrioid neoplasms: Experience with eight cases. Diagnostic Cytopathology, 2009, 37, 347-352.	1.0	7
176	Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecologic Oncology, 2019, 154, 255-258.	1.4	7
177	Clinical trials and drug cost savings for Italian health service. BMC Health Services Research, 2020, 20, 1089.	2.2	7
178	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. Cancers, 2021, 13, 5152.	3.7	7
179	Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. Critical Reviews in Oncology/Hematology, 2003, 46, 285-295.	4.4	6
180	New biological treatments for gynecological tumors: focus on angiogenesis. Expert Opinion on Biological Therapy, 2014, 14, 337-346.	3.1	6

#	ARTICLE	IF	CITATIONS
181	Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01â€“2014). BMC Cancer, 2017, 17, 493.	2.6	6
182	Joint ENGOT and GOG Foundation requirements for trials with industry partners. International Journal of Gynecological Cancer, 2019, 29, 1094-1097.	2.5	6
183	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. PLoS ONE, 2019, 14, e0210330.	2.5	6
184	Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing. Journal of Clinical Oncology, 2020, 38, 172-173.	1.6	6
185	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. Cancers, 2020, 12, 2239.	3.7	6
186	An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear. Journal of Cancer, 2021, 12, 4443-4454.	2.5	5
187	Subcutaneous Seeding of Hepatocellular Carcinoma After Fine-needle Percutaneous Biopsy. Journal of Clinical Gastroenterology, 2001, 33, 171.	2.2	5
188	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. International Journal of Gynecological Cancer, 2022, 32, 1205-1207.	2.5	5
189	A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer. Oncology, 1999, 56, 267-273.	1.9	4
190	Stop Flow in abdominal and pelvic cancer relapses. Frontiers in Bioscience - Landmark, 2006, 11, 1284.	3.0	4
191	From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. Frontiers in Pharmacology, 2016, 7, 110.	3.5	4
192	Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. Cancers, 2021, 13, 1544.	3.7	4
193	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. International Journal of Gynecological Cancer, 2021, 31, ijgc-2020-002343.	2.5	4
194	Real-world experience with trabectedin for the treatment of recurrent ovarian cancer. Expert Review of Anticancer Therapy, 2021, 21, 1089-1095.	2.4	4
195	Patterns of progression and subsequent management of patients with <i>BRCA1/2</i> mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).. Journal of Clinical Oncology, 2020, 38, 6070-6070.	1.6	4
196	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). Immunotherapy, 2022, 14, 107-114.	2.0	4
197	Management of Metastatic Endometrial Cancer: Physiciansâ€™ Choices Beyond the First Line. A MITO Survey. Frontiers in Oncology, 0, 12, .	2.8	4
198	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, .	4.4	4

#	ARTICLE	IF	CITATIONS
199	Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non-Platinum-Based Chemotherapy. <i>Clinical Ovarian Cancer & Other Gynecological Malignancies</i> , 2008, 1, 139-140.	0.2	3
200	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer – Authors' reply. <i>Lancet Oncology</i> , 2014, 15, e250-e251.	10.7	3
201	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	2.6	3
202	European Network of Gynaecological Oncological Trial Groups™ requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 730-734.	2.5	3
203	Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 110-113.	2.5	3
204	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	2.5	3
205	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1363-1368.	2.5	3
206	Validation of MiROvar, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. <i>European Journal of Cancer</i> , 2022, 161, 55-63.	2.8	3
207	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 1849.	3.7	3
208	Reirradiation of Locally Recurrent Prostate Cancer with Cyberknife® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity®: Outcomes, Toxicities and Dosimetric Evaluation. <i>Cancers</i> , 2022, 14, 3187.	3.7	3
209	Postheparin plasma diamine oxidase in subjects with celiac disease. <i>Gastroenterology</i> , 1991, 100, 583-584.	1.3	2
210	From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. <i>Immunotherapy</i> , 2021, 13, 67-77.	2.0	2
211	A miRNA signature assessing ovarian cancer prognosis. <i>Oncoscience</i> , 2016, 3, 308-310.	2.2	2
212	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 799-803.	2.5	2
213	Having progress with upfront chemotherapy in ovarian cancer. Is it still a possible goal?. <i>European Journal of Cancer</i> , 2010, 46, 2140-2142.	2.8	1
214	Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens. <i>International Journal of Clinical Oncology</i> , 2012, 17, 385-389.	2.2	1
215	The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1094-1095.	2.5	1
216	Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. <i>Supportive Care in Cancer</i> , 2017, 25, 1743-1748.	2.2	1

#	ARTICLE	IF	CITATIONS
217	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. <i>Future Oncology</i> , 2019, 15, 2657-2666.	2.4	1
218	Cytological diagnosis of Xp11 translocation renal cell carcinoma: An unusual suspect in bone metastases from unknown primary malignancies. <i>Diagnostic Cytopathology</i> , 2021, 49, 11-17.	1.0	1
219	How to sequence treatment in relapsed ovarian cancer. <i>Future Oncology</i> , 2021, 17, 1-8.	2.4	1
220	Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis. <i>European Journal of Cancer</i> , 2021, 152, 257-258.	2.8	1
221	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16013-e16013.	1.6	1
222	How to Design Clinical Trials?. , 2016, , 79-93.		1
223	miRNA-based signature for predicting epithelial ovarian cancer recurrence. <i>Translational Cancer Research</i> , 2017, 6, S232-S234.	1.0	1
224	Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	1
225	Single Agents or Combination Chemotherapy for Advanced Ovarian Carcinoma in Elderly Patients: Pro Single Agents. <i>Tumori</i> , 2002, 88, S117-S119.	1.1	0
226	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
227	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
228	First-Line Systemic Therapy (Chemo/Antiangiogenics). , 2017, , 95-112.		0